TaiMed Biologics Inc. (TPEX:4147)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
64.90
+2.20 (3.51%)
Sep 8, 2026, 12:50 PM CST

TaiMed Biologics Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-138.9-167.78-201.83-194.81-269.29-470.93
Depreciation & Amortization
150.77150.47150.1150.67151.73152.13
Other Amortization
3.133.144.184.724.724.53
Loss (Gain) From Sale of Assets
1.581.612.32--24.18
Loss (Gain) From Sale of Investments
-1.280.69-29.05122.81-26.76
Stock-Based Compensation
12.438.7725.3610.5112.2710.22
Other Operating Activities
49.980.6880.785.82168.85101.38
Change in Accounts Receivable
27.2623.9557.47-62.2459.5497.94
Change in Inventory
97.6389.44185.47110.85-382.8414.84
Change in Accounts Payable
-2.0880.25-12.7413.41-122.49116.79
Change in Unearned Revenue
-79.48-79.01-113.31-27.93-339.16113.91
Change in Other Net Operating Assets
34.16-1.06-557.36-65.64-11.33-349.5
Operating Cash Flow
155.12191.14-379.55-25.6-605.21-211.28
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-47.11-22.67-8.06-6.15-3.56-9.69
Sale of Property, Plant & Equipment
-----0.41
Sale (Purchase) of Intangibles
-0.1-0.1-11.3--1.21-3.87
Investment in Securities
336.19176.7-695.39-12.88110.88204.07
Other Investing Activities
-0.530.09-0.12.58--
Investing Cash Flow
288.45154.02-714.84-16.46106.12190.92

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
----200-
Total Debt Issued
----200-
Short-Term Debt Repaid
---200---
Long-Term Debt Repaid
--29.5-28.98-16.05-1.98-1.93
Lease Payments
-2.27-2.26-2.24-2.05-1.98-1.93
Total Debt Repaid
-29.81-29.5-228.98-16.05-1.98-1.93
Net Debt Issued (Repaid)
-29.81-29.5-228.98-16.05198.02-1.93
Issuance of Common Stock
0.278.781,64535.2810.314.71
Other Financing Activities
-0.92-0.92-4.27-0.050.01
Financing Cash Flow
-164.53-21.641,41219.23208.382.79

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
13.87-5.3711.54-0.2813.21-2.9
Net Cash Flow
292.91318.15329.22-23.1-277.51-20.47

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
108.01168.48-387.61-31.75-608.77-220.96
Free Cash Flow Growth
------
Free Cash Flow Margin
17.44%27.56%-63.52%-6.46%-108.13%-53.44%
Free Cash Flow Per Share
0.400.62-1.45-0.13-2.41-0.88
Levered Free Cash Flow
210.15316.45-268.4782.39-217.42-191.55
Unlevered Free Cash Flow
216.65323.14-260.5991.65-211.11-186.9
Free Cash Flow After Leases
105.73166.21-389.85-33.81-610.74-222.89

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
10.4210.7412.7114.769.887.44
Change in Working Capital
77.49113.57-440.47-31.56-796.29-6.02